Immucillins, 17 | 1219216-83-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: Immucillins, 17
• 英文别名: 7-[3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-3,5-dihydropyrrolo[3,2-d]pyrimidin-4-one
• CAS: 1219216-83-7
• 化学式: C₁₁H₁₄N₄O₄
• 分子量: 266.25
• InChiKey: IWKXDMQDITUYRK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  130
• 氢给体数：
  6
• 氢受体数：
  5

文献信息

• Process for preparing inhibitors of nucleoside metabolism
  申请人：Furneaux Hubert Richard

  公开号：US20070161667A1

  公开（公告）日：2007-07-12

  A process of preparing a compound of the formula (I) wherein B is chosen from OH, NH 2 , NHR, H or halogen; D is chosen from OH, NH 2 , NHR, H halogen or SCH 3 ; R is an optionally substituted alkyl, aralkyl or aryl group; and Z is selected from OH, hydrogen, halogen, hydroxy, SQ or OQ, Q is an optionally substituted alkyl, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof, which comprises reacting a compound of the formula (II) with an anion produced by abstraction of the bromine or iodine atom from a compound of formula (XIX),

  制备公式（I）化合物的过程，其中B选自OH，NH2，NHR，H或卤素；D选自OH，NH2，NHR，H，卤素或SCH3；R是可选取的取代基的烷基，芳基烷基或芳基；Z选自OH，氢，卤素，羟基，SQ或OQ，Q是可选取的取代基的烷基，芳基烷基或芳基；或其互变异构体；或其药学上可接受的盐；或其酯；或其前药。该过程包括将公式（II）化合物与从公式（XIX）化合物中提取溴或碘原子所产生的阴离子反应。
• Inhibitors of nucleoside metabolism
  申请人：Furneaux Hubert Richard

  公开号：US20070197561A1

  公开（公告）日：2007-08-23

  The present invention provides compounds having the formula: wherein A is CH or N; B is chosen from OH, NH 2 , NHR, H or halogen; D is chosen from OH, NH 2 , NHR, H, halogen or SCH 3 ; R is an optionally substituted alkyl, aralkyl or aryl group; and X and Y are independently selected from H, OH or halogen except that when one of X and Y is hydroxy or halogen, the other is hydrogen; and Z is OH or, when X is hydroxy, Z is selected from hydrogen, halogen, hydroxy, SQ or OQ, Q is an optionally substituted alkyl, aralkyl or aryl group; or a tautomer thereof; or a pharmaceutically acceptable salt thereof; or an ester thereof; or a prodrug thereof; and compounds having the formula: wherein A, X, Y, Z and R are defined for compounds of formula (I) where first shown above; E is chosen from CO 2 H or a corresponding salt form, CO 2 R, CN, CONH 2 , CONHR or CONR 2 ; and G is chosen from NH 2 , NHCOR, NHCONHR or NHCSNHR; or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof. The present invention also provides the use of the above compounds as pharmaceuticals, pharmaceutical compositions containing the compounds and processes for preparing the compounds.

  本发明提供具有以下结构式的化合物：其中A为CH或N；B选择自OH、NH2、NHR、H或卤素；D选择自OH、NH2、NHR、H、卤素或SCH3；R为可选取代的烷基、芳基烷基或芳基基团；X和Y独立选择自H、OH或卤素，除非其中一个为羟基或卤素，另一个为氢；Z为OH或者当X为羟基时，Z选择自氢、卤素、羟基、SQ或OQ，Q为可选取代的烷基、芳基烷基或芳基基团；或其互变异构体；或其药学上可接受的盐；或其酯；或其前药。本发明还提供具有以下结构式的化合物：其中A、X、Y、Z和R的定义与上述第一种结构式的化合物相同；E选择自CO2H或相应的盐形式、CO2R、CN、CONH2、CONHR或CONR2；G选择自NH2、NHCOR、NHCONHR或NHCSNHR；或其互变异构体、药学上可接受的盐、酯或前药。本发明还提供上述化合物作为药物的用途、含有该化合物的药物组合物以及制备该化合物的方法。
• COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS
  申请人：Sinclair David A.

  公开号：US20120029065A1

  公开（公告）日：2012-02-02

  Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively.

  本文提供了一种调节sirtuin活性或水平的方法和组合物，从而治疗或预防主体的肥胖症或胰岛素抵抗性疾病，如糖尿病。示例方法包括使用sirtuin激活化合物或抑制性化合物与细胞接触，从而分别增加或减少脂肪积累。
• Use of purine analogues for treating airway diseases
  申请人：Merck Serono S.A.

  公开号：EP2343074A1

  公开（公告）日：2011-07-13

  The present invention relates to the treatment and prophylaxis of asthma and other airway dysfunctions, diseases and/or symptoms thereof, more particularly the present invention relates to the use of cytostatic and/or cytotoxic purine analogues for such treatment and prophylaxis.

  本发明涉及哮喘和其他气道功能障碍、疾病和/或症状的治疗和预防，尤其是本发明涉及细胞抑制剂和/或细胞毒性嘌呤类似物在此类治疗和预防中的应用。
• COMPOSITIONS AND METHODS FOR POTENTIATING IMMUNE RESPONSE, ENHANCING IMMUNOTHERAPY, AND INCREASING VACCINE POTENCY
  申请人：Nitor Therapeutics

  公开号：EP3010340A2

  公开（公告）日：2016-04-27